GPN Vaccines Raises $10 Million To Advance Gamma-PN Pneumococcal Vaccine Toward Phase 2 Trials
· pulse2.com · popularity 17/100 · 0 similar stories today · Genetics, Genomics & Biotech (Science)
Read the original at pulse2.com →
Summary
GPN Vaccines, a clinical-stage biotechnology company developing broadly protective bacterial vaccines, has closed a fully subscribed $10 million private placement with participation from new and existing investors. The financing will support preparations to advance its lead investigational vaccine, Gamma-PN, into Phase 2 clinical development. The post GPN Vaccines Raises $10 Million To Advance Gamma-PN Pneumococcal Vaccine Toward Phase 2 Trials appeared first on Pulse 2.0 .
Found in: Pulse 2.0. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 14.